Lv11
68 积分 2026-08-11 加入
Cancer drug resistance: an evolving paradigm
23天前
已完结
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
24天前
已完结
Activation of YBX1 and JAK2/STAT3 pathways by RIOK1 increases lenvatinib resistance in hepatocellular carcinoma cells
24天前
已完结
U2SURP increases CREB3L2 RNA stability and RIOK1 transcription to enhance lenvatinib resistance in hepatocellular carcinoma cells
24天前
已完结
Hallmarks of Cancer: New Dimensions
2个月前
已完结
Hepatocellular carcinoma
2个月前
已完结
皖公网安备34019202002308
